News

Please click title link for the download page.

Broadly good, but a few surprises: raltegravir alternative to efavirenz, limited use of generics, no need to switch stable patients…

A new Latvian translation of the i-Base guide to HIV, Pregnancy and Women’s Health is now online. This is the fourth i-Base guide to be translated into Latvian, in collaboration with Association HIV.LV and the EATG COPE project. HIV, pregnancy …

Reports from EASL, BHIVA and CROI: new hepatitis C drugs, including pricing and UK access; ARVs in pregnancy; early use in babies; tenofovir in Zambia; US guidelines for treatment and PrEP; all this and more…

SCART is a UK study for HIV-related Kaposi’s Sarcoma (KS). It uses an experimental cancer drug called selumetinib. KS is a type of cancer that is more common in HIV positive people although it is much less common now that …

A ‘rapid report’ covering the numerous new and upcoming drugs for hepatitis C – plus new guidelines from WHO and EASL…

The TAILOR study plans to enrol almost 400 HIV positive people who are already on stable HIV treatment. It will use different doses of telmisartan (20 mg, 400 mg and 80 mg) to see whether this reduces the risks of …

CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments…

First reports from CROI 2014: no linked HIV transmissions when viral load is suppressed; 3-monthly PrEP injections, PI/r monotherapy, ACTG 5257, NEAT001, paediatric ARV pipeline, low dose efavirenz and more…

Women and HIV, research update on HIV persistence and cure, sofosbuvir approved for hepatitis C in the US and Europe, priced at $1000 a day…

TB treatment for children, reports from EACS, global funding for treatment, efavirenz and risk of suicide, i-Base job vacancies…

The study that could stop your next HIV test coming back positive…

UK cinema launch of the compelling documentary about the people who fought for the drugs we use today. Meet the director and other activists.

i-Base have a vacancy for a new advocate to join the team. We also are looking at freelance writers to contribute to HIV Treatment Bulletin. Full details.

NOTE: EU granted full approval for elvitegravir on 18 November 2013. ……………… On 19 September 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation in Europe for the integrase inhibitor elvitegravir 85 …

ICAAC and IAS conferences; CROI archive website still blocked; cobicistat approved in the EU, Stribild in England, dolutegravir in the US – and pricing in the UK and globally…

Alternative booster for atazanavir and darunavir approved…

Important decision by NHS England under its new commissioning structure about access to a new HIV drug.

Dolutegravir has disappointingly been priced in the US above existing integrase inhibitors…

Over 20 reports from three leading conferences: 7th IAS conference, 5th Paediatric Workshop and International Drug Resistance Workshop. Plus phasing out d4T, plans for new tenofovir and where is the CROI website?